Amphastar Pharmaceuticals, Inc. (AMPH) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Amphastar Pharmaceuticals, Inc.'s filing signal turned negative.

Amphastar Pharmaceuticals develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, along with active pharmaceutical ingredients (APIs). The company's largest revenue drivers include BAQSIMI (glucagon nasal powder), Primatene MIST (epinephrine), glucagon for injection, epinephrine, and lidocaine. Amphastar strategically focuses on products with high technical barriers to market entry, leveraging capabilities in complex molecule characterization, peptide and protein synthesis, and advanced drug delivery. The company operates manufacturing facilities in the United States, France, and China, and has expanded its global footprint through strategic acquisitions and licensing agreements. For the year ended December 31, 2025, Amphastar recorded net revenues of $719.9 million.

Primary revenue drivers include sales of BAQSIMI, Primatene MIST, glucagon, epinephrine, and lidocaine. The company also generates revenue from the sale of APIs and contract manufacturing services.